At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential.

For the 2nd year, network with the KOLs and RNA pioneers, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA.

Download the Full Event Guide.

With 22 world-class speakers sharing their latest findings, join those who are re-defining the undruggable nature of RNA:

• Kevin Weeks, Founder of Ribometrix; Professor of Chemistrym, University of North Carolina
• Frank Slack, Co-Founder of Twentyeight-Seven Therapeutics; Professor, BIDMC
• Kathryn McCabe, Sr. Director of Business Development, Eli Lilly
• Martin Pettersson, Research Fellow, Pfizer
• Christopher Barbieri, Senior Investigator, Bristol-Myers Squibb
• Jennifer Petter, Founder & CSO, Arrakis Therapeutics
• Yochi Slonim, Co-founder & CEO, Anima Biotech
• Gerhard Mueller, CSO, Gotham Therapeutics
• Christopher R. Trotta, VP, Biology, PTC Therapeutics

This is only some of the senior experts confirmed to present – check out the full speaker faculty and case studies here.

Once again join your RNA community at this translational and industry dedicated event focused on optimizing target validation, improving drug-like properties & accelerating the translation of selective and bioactive RNA targeted small molecule therapeutics into human clinical trials.

Check out the official event guide for full speaker details or if you’re ready to register, secure your place here.